Saturday, December 2, 2023
OANDP-L
  • Login
No Result
View All Result
The O&P EDGE
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
No Result
View All Result
The O&P EDGE Magazine
No Result
View All Result
Home News

Leading Experts Call for Making Cancer Drugs More Affordable

by The O&P EDGE
July 31, 2015
in News
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

A group of 118 of the nation’s leading cancer experts have drafted a prescription for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. Their recommendations and support are outlined in a commentary, co-authored by the group, in the journal Mayo Clinic Proceedings.

“High cancer drug prices are affecting the care of patients with cancer and our healthcare system,” said lead author Ayalew Tefferi, MD, a hematologist at Mayo Clinic. “The average gross household income in the U.S. is about $52,000 per year. For an insured patient with cancer who needs a drug that costs $120,000 per year, the out-of-pocket expenses could be as much as $25,000 to $30,000-more than half their average household income.”

The group cites a 2015 study published in the Journal of Economic Perspectives, which found that cancer drug prices have risen by an average of $8,500 per year over the past 15 years.

“When you consider that cancer will affect one in three individuals over their lifetime, and [with] recent trends in insurance coverage [that] put a heavy financial burden on patients with out-of-pocket expenses, you quickly see that the situation is not sustainable,” Tefferi said. “It’s time for patients and their physicians to call for change.”

The group says the following actions would improve the situation and allow market forces to work better:

  • Create a post-U.S. Food and Drug Administration drug-approval review mechanism to propose a fair price for new treatments based on the value to patients and healthcare
  • Allow Medicare to negotiate drug prices
  • Allow the Patient-Centered Outcomes Research Institute and similar organizations to evaluate the benefits of new treatments and to include drug prices in their assessments of the treatment value
  • Allow importation of cancer drugs across borders for personal use (for example, prices in Canada are about half of prices in the U.S.)
  • Pass legislation to prevent drug companies from delaying access to generic drugs
  • Reform the patent system to make it more difficult to prolong product exclusivity unnecessarily
  • Encourage organizations that represent cancer specialists and patients (e.g., American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, American Cancer Society, National Comprehensive Cancer Network) to consider the overall value of drugs and treatments in formulating treatment guidelines

The group also supports the patient-based, grassroots movement on change.org that advocates against high cancer drug prices with the goal of drawing the attention of pharmaceutical companies and elected representatives to this issue. The authors write, “With proper support of these grassroots efforts and proper use of that support downstream, it should be possible to focus the attention of pharmaceutical companies on this problem and to encourage our elected representatives to more effectively advocate for the interests of their most important constituents among the stakeholders in cancer-American cancer patients.”

This article was adapted from information provided by Mayo Clinic.

Related posts:

  1. NAAOP Analyzes Medicare Bill
  2. Cancer Drugs: Are They a Good Value?
  3. New Device May Help Identify Best Cancer Drugs for Each Patient
  4. The Dobson DaVanzo Report: What It Says and Why It Matters
Previous Post

NAAOP Issues Call to Action to Protect Access to Prosthetic Limbs and Appropriate Care

Next Post

A Symbiosis: Pedorthists & Podiatrists Working Together

Next Post

A Symbiosis: Pedorthists & Podiatrists Working Together

  • VIEW CURRENT ISSUE
  • SUBSCRIBE FOR FREE

RECENT NEWS

News

Factors Identified to Maximize Telehealth Walking Self-management Intervention

by The O&P EDGE
November 21, 2023

Researchers conducted a study in an effort to understand therapist-identified factors influencing clinical adoption of a telehealth walking self-management intervention...

Read more

Wearable Hand Orthosis Aids Child in Daily Life

Minimal Exercise Can Benefit Lower-limb Amputees

Prosthetist Named Chief Clinical Officer

Get unlimited access!

Join EDGE ADVANTAGE and unlock The O&P EDGE's vast library of archived content.
SUBSCRIBE TODAY

O&P JOBS

Eastern

Certified Pedorthist

Central

Clinical Manager

Central

Certified Prosthetist/Orthotist (CP/CPO)

 

© 2023 The O&P EDGE

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

CONTACT US

866-613-0257

[email protected]

201 E. 4th St
Loveland, CO 80537

The most important industry news and events delivered directly to your inbox every week.

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

© 2023 The O&P EDGE

No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2023 The O&P EDGE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.